Rapport Therapeutics, Inc. (RAPP)
$48.81-$2.06 (-4.05%) Today
Abraham Ceesay - Officer
Krishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerKrishnaswamy Yeleswaram - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerAbraham Ceesay - OfficerRapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 20 | 149,624 | $7.09M |
| Grant or award | 8 | 121,600 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
61 Form 4 filings on record, the earliest from Nov 7, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
 Troy A. Ignelzi - Officer | Grant or award | Stock Option (Right to Buy) | 148,000 | $0.00 | - | |
| Krishnaswamy Yeleswaram - Officer | Grant or award | Stock Option (Right to Buy) | 120,000 | $0.00 | - | |
| David Bredt - Officer | Grant or award | Stock Option (Right to Buy) | 103,000 | $0.00 | - | |
| Cheryl Gault - Officer | Grant or award | Stock Option (Right to Buy) | 132,000 | $0.00 | - | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 5,833 | $26.12 | $152K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 5,083 | $26.11 | $133K | |
| David Bredt - Officer | Open-market sale | Common Stock | 8,300 | $26.83 | $223K | |
| David Bredt - Officer | Open-market sale | Common Stock | 200 | $27.40 | $5K | |
| David Bredt - Officer | Grant or award | Common Stock | 18,000 | - | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 6,567 | $30.05 | $197K | |
| Krishnaswamy Yeleswaram - Officer | Grant or award | Common Stock | 9,000 | - | - | |
| Krishnaswamy Yeleswaram - Officer | Open-market sale | Common Stock | 2,840 | $30.05 | $85K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,441 | $28.84 | $70K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,792 | $30.04 | $84K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 600 | $31.04 | $19K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,147 | $28.84 | $62K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,421 | $30.04 | $73K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 515 | $31.04 | $16K | |
| David Bredt - Officer | Open-market sale | Common Stock | 7,704 | $29.95 | $231K | |
| David Bredt - Officer | Open-market sale | Common Stock | 796 | $30.68 | $24K | |
| Cheryl Gault - Officer | Option exercise | Common Stock | 5,000 | $1.80 | $9K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 5,000 | $30.10 | $150K | |
| Cheryl Gault - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 5,344 | $25.39 | $136K | |
| David Bredt - Officer | Open-market sale | Common Stock | 3,156 | $24.84 | $78K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,777 | $24.92 | $69K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 3,056 | $25.43 | $78K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,242 | $24.91 | $56K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 2,841 | $25.44 | $72K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 4,647 | $25.72 | $120K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 1,186 | $26.14 | $31K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 4,328 | $25.75 | $111K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 755 | $26.17 | $20K | |
| David Bredt - Officer | Open-market sale | Common Stock | 7,418 | $25.73 | $191K | |
| David Bredt - Officer | Open-market sale | Common Stock | 1,082 | $26.16 | $28K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 39,435 | $26.30 | $1.04M | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 1,400 | $26.87 | $38K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 34,885 | $26.30 | $918K | |
| Abraham Ceesay - Officer | Open-market sale | Common Stock | 700 | $27.04 | $19K | |
| Reid M. Huber | Open-market purchase | Common Stock | 20,400 | $24.48 | $499K | |
 Steven M. Paul | Open-market purchase | Common Stock | 28,284 | $24.50 | $693K | |
| Steven M. Paul | Open-market purchase | Common Stock | 13,382 | $24.97 | $334K | |
| David Bredt - Officer | Open-market sale | Common Stock | 5,098 | $23.88 | $122K | |
| David Bredt - Officer | Open-market sale | Common Stock | 3,402 | $24.66 | $84K | |
| Wendy B. Young | Open-market purchase | Common Stock | 3,500 | $22.60 | $79K | |
| Cheryl Gault - Officer | Option exercise | Common Stock | 5,000 | $1.80 | $9K | |
| Cheryl Gault - Officer | Open-market sale | Common Stock | 5,000 | $38.33 | $192K | |
| Cheryl Gault - Officer | Option exercise | Stock Option (Right to Buy) | 5,000 | $0.00 | - | |
| David Bredt - Officer | Open-market sale | Common Stock | 8,300 | $14.98 | $124K | |
| David Bredt - Officer | Open-market sale | Common Stock | 200 | $15.79 | $3K | |
| David Bredt - Officer | Open-market sale | Common Stock | 8,500 | $14.00 | $119K | |
| Steven M. Paul | Grant or award | Stock Option (Right to Buy) | 21,850 | $0.00 | - | |
| John Maraganore | Grant or award | Stock Option (Right to Buy) | 21,850 | $0.00 | - | |
| Robert J. Perez | Grant or award | Stock Option (Right to Buy) | 10,925 | $0.00 | - | |
| James Healy | Grant or award | Stock Option (Right to Buy) | 21,850 | $0.00 | - | |
| Wendy B. Young | Grant or award | Stock Option (Right to Buy) | 29,756 | $0.00 | - | |
| Robert J. Perez | Grant or award | Stock Option (Right to Buy) | 29,756 | $0.00 | - | |
| Ramiro Sanchez | Grant or award | Stock Option (Right to Buy) | 29,756 | $0.00 | - |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| KRISHNASWAMY YELESWARAM | Officer | 37,000 | $1.83M | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 11,472 | $553K | View on EDGAR | |
| KRISHNASWAMY YELESWARAM | Officer | 2,092 | $103K | View on EDGAR |
Rapport Therapeutics, Inc. (RAPP) had 16 insider filings in the last 90 days, with the most recent on 2026-08-26. The full record for RAPP runs to 61 Form 4 filings, the earliest from 2024-11-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of RAPP were filed in the last 90 days. 4 purchases are on record for this company.
20 insider sales of RAPP were filed in the last 90 days, totaling $7.09M.
This page tracks RAPP Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add RAPP to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
